Demski David M 4
4 · GLOBUS MEDICAL INC · Filed Apr 27, 2021
Insider Transaction Report
Form 4
Demski David M
DirectorPresident and COO
Transactions
- Exercise/Conversion
Class A Common Stock
2021-04-23$43.77/sh+21,875$957,469→ 21,875 total - Exercise/Conversion
Class A Common Stock
2021-04-23$29.31/sh+22,821$668,884→ 66,571 total - Exercise/Conversion
Class A Common Stock
2021-04-23$43.58/sh+21,875$953,313→ 43,750 total - Exercise/Conversion
Stock Option (Right to Buy Class A Common Stock)
2021-04-23−22,821→ 97,179 totalExercise: $29.31Exp: 2027-08-28→ Class A Common Stock (22,821 underlying) - Exercise/Conversion
Stock Option (Right to Buy Class A Common Stock)
2021-04-26−78,334→ 0 totalExercise: $26.27Exp: 2027-01-30→ Class A Common Stock (78,334 underlying) - Exercise/Conversion
Stock Option (Right to Buy Class A Common Stock)
2021-04-23−21,875→ 28,125 totalExercise: $43.77Exp: 2028-01-22→ Class A Common Stock (21,875 underlying) - Exercise/Conversion
Stock Option (Right to Buy Class A Common Stock)
2021-04-23−54,688→ 120,312 totalExercise: $53.27Exp: 2030-01-22→ Class A Common Stock (54,688 underlying) - Exercise/Conversion
Class A Common Stock
2021-04-23$53.27/sh+54,688$2,913,230→ 121,259 total - Exercise/Conversion
Stock Option (Right to Buy Class A Common Stock)
2021-04-23−21,875→ 65,625 totalExercise: $43.58Exp: 2029-01-22→ Class A Common Stock (21,875 underlying) - Exercise/Conversion
Stock Option (Right to Buy Class A Common Stock)
2021-04-26−65,929→ 31,250 totalExercise: $29.31Exp: 2027-08-28→ Class A Common Stock (65,929 underlying) - Sale
Class A Common Stock
2021-04-23$71.59/sh−121,259$8,680,932→ 0 total - Exercise/Conversion
Class A Common Stock
2021-04-26$26.27/sh+78,334$2,057,834→ 78,334 total - Exercise/Conversion
Class A Common Stock
2021-04-26$29.31/sh+65,929$1,932,379→ 144,263 total - Sale
Class A Common Stock
2021-04-26$71.50/sh−144,263$10,314,805→ 0 total
Footnotes (8)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.50 to $71.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.50 to $71.53, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- [F4]These options were granted on January 22, 2018, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2019, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
- [F5]These options were granted on January 22, 2019, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2020, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
- [F6]These options were granted on August 28, 2017, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on August 28, 2018, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
- [F7]These options were granted on January 22, 2020, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2021, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
- [F8]These options were granted on January 30, 2017, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2018, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.